TMBIM4 and psychotic disorder: The S1R binding site is the target of numerous pharmacological studies on psychotic disorders [2], locomotor activity [3], threat response [4], and pain [5] etc. Many S1R-binding compounds have been identified [6]; some are in clinical use (e.g., as antidepressants) [7] or trials [8].